NervGen Pharma Corp. (NGEN)
2.00
+0.14
(+7.53%)
USD |
NASDAQ |
Aug 24, 16:00
2.01
+0.01
(+0.50%)
After-Hours: 06:22
NervGen Pharma Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.0024 |
| September 30, 2025 | -0.0113 |
| June 30, 2025 | -0.0628 |
| March 31, 2025 | 0.0589 |
| December 31, 2024 | 0.041 |
| September 30, 2024 | 0.0141 |
| June 30, 2024 | 0.0122 |
| March 31, 2024 | 0.0093 |
| December 31, 2023 | -0.0981 |
| September 30, 2023 | 0.0429 |
| June 30, 2023 | 0.0319 |
| March 31, 2023 | 0.0266 |
| December 31, 2022 | 0.0211 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.0165 |
| June 30, 2022 | 0.0329 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| InMed Pharmaceuticals, Inc. | 0.061 |
| Milestone Pharmaceuticals, Inc. | 7.785 |
| Clearmind Medicine, Inc. | 0.0075 |
| Lexaria Bioscience Corp. | 0.0183 |
| Target Group, Inc. (Canada) | -1.291 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 63.57M |
| Total Liabilities (Quarterly) | 51.39M |
| Shareholders Equity (Quarterly) | 12.18M |
| Current Ratio | 1.232 |
| Net Debt Paydown Yield | 0.01% |